One-year outcomes of the head to head trial between CoreValve Evolut R vs Sapien 3 showed a significantly higher difference in stroke vs. patients receiving the self-expanding valve (Sapien 3 6.9% vs Evolut R 1%; p=0.002). The SOLVE-TAVI randomized 2×2 patients with severe aortic stenosis and high surgical risk to Sapien 3 or Evolut R andref="https://solaci.org/en/2020/10/21/tct-2020-surprising-differences-in-stroke-between-sapien-3-and-evolut-r/" title="Read more" >...
After reports of some serious adverse events with first-generation Lotus, the device was pulled off the market—but it was not meant to be left in oblivion. Now, it is back, renewed and with the approval of the United States Food and Drug Administration (FDA), to compete directly with the two market leaders (Sapien and CoreValve),ref="https://solaci.org/en/2019/04/29/lotus-returns-with-new-strength-and-the-fda-approval-to-compete-with-sapien3-and-corevalve-evolut-r/" title="Read more" >...
Two recent articles featured in JACC Cardiovascular Interventions showed that short term (at 30 days) outcomes of patients treated with the next-generation self-expanding Medtronic Evolut R valves could present several advantages compared to the original CoreValve, including recapturability. Both analyses reported similar rates of all-cause mortality and stroke. The study carried out by Dr. Jeffrey Popma asref="https://solaci.org/en/2017/02/23/evolut-r-clinical-results-might-be-better-than-those-for-first-generation-corevalve/" title="Read more" >...
Original Title: Treatment of Symptomatic Severe Aortic Stenosis with a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. Reference: Ganesh Manoharan et al. J Am Coll Cardiol Intv. 2015; 8(10):1359-1367. Courtesy of Dr. Agustín Vecchia. Despite the rapid growth and evolution of transcatheter aortic valve replacement devices (TAVR), vascular access complications, paravalvular leak, strokeref="https://solaci.org/en/2016/07/08/medtronics-new-corevalve-evolut-r-for-tavr/" title="Read more" >...
Live Case Broadcasted by TBR Productions from Toulouse, France to Rio de Janeiro, Brazil, where took place the SOLACI-SBHCI 2016 Congress. Panelists: Rafael Cavalcante e Silva – BRAZIL, Patrick W. Serruys – UK, Samir Kapadia – USA, Jorge Atilio Belardi – ARGENTINA.
This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve. All maneuvers were carried out successfully. A 30ref="https://solaci.org/en/2015/06/24/congress-item-9009/" title="Read more" >...
The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients. So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates. Researchers looked into theref="https://solaci.org/en/2024/03/15/tender-study-evolution-at-one-year/" title="Read more" >...
Infiltrative diseases (ID) consist of a heterogeneous series of genetic conditions that cause infiltration and extracellular deposits which alter the diverse systems and organs affected. Amyloidosis, sarcoidosis and hemochromatosis affect the heart, altering the myocardium and the conduction system. PCI is often used at present to treat heart disease, and some of these patients presentref="https://solaci.org/en/2024/02/21/pci-evolution-in-infiltrative-diseases/" title="Read more" >...
The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR. One of the fundamental questions that still remains unanswered revolves around deviceref="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...
Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality. In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others. In the analysisref="https://solaci.org/en/2024/01/18/tricvalve-12-month-evolution/" title="Read more" >...